Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of Intravenous Infusions of E2814 in Healthy Subjects
Conditions
Interventions
E2814
E2814-matched placebo
Locations
2
United States
California Clinical Trials Medical Group/Parexel International
Glendale, California, United States
Worldwide Clinical Trials
San Antonio, Texas, United States
Start Date
December 16, 2019
Primary Completion Date
March 9, 2023
Completion Date
March 9, 2023
Last Updated
April 6, 2023
NCT00104325
NCT01399385
NCT05774834
NCT07310264
NCT06904807
NCT06342713
Lead Sponsor
Eisai Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions